Omeros (OMER) Rating Increased to Hold at Zacks Investment Research
Omeros (NASDAQ:OMER) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
Other equities research analysts also recently issued reports about the stock. Maxim Group set a $25.00 price target on shares of Omeros and gave the company a “buy” rating in a research note on Sunday, May 13th. ValuEngine raised shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, May 12th. HC Wainwright set a $34.00 price target on shares of Omeros and gave the company a “buy” rating in a research note on Friday, May 11th. Finally, Seaport Global Securities initiated coverage on shares of Omeros in a research note on Thursday, July 12th. They issued a “buy” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $27.56.
Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.04). The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same period in the prior year, the business posted ($0.33) earnings per share. The company’s quarterly revenue was down 90.1% on a year-over-year basis. equities analysts predict that Omeros will post -2.42 earnings per share for the current year.
In other news, VP Marcia S. Kelbon sold 40,723 shares of the business’s stock in a transaction dated Friday, July 27th. The shares were sold at an average price of $21.56, for a total transaction of $877,987.88. Following the completion of the sale, the vice president now directly owns 219,645 shares of the company’s stock, valued at $4,735,546.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Marcia S. Kelbon sold 4,277 shares of the business’s stock in a transaction dated Thursday, July 12th. The stock was sold at an average price of $21.48, for a total transaction of $91,869.96. Following the sale, the vice president now directly owns 188,922 shares of the company’s stock, valued at $4,058,044.56. The disclosure for this sale can be found here. Insiders own 12.10% of the company’s stock.
Large investors have recently bought and sold shares of the company. BlueMountain Capital Management LLC bought a new stake in shares of Omeros during the second quarter worth about $118,000. Quad Cities Investment Group LLC bought a new stake in shares of Omeros during the second quarter worth about $161,000. Belpointe Asset Management LLC bought a new stake in shares of Omeros during the second quarter worth about $204,000. Claraphi Advisory Network LLC bought a new stake in Omeros in the 1st quarter worth about $134,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Omeros in the 2nd quarter worth about $274,000. 48.14% of the stock is owned by institutional investors.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.